CME/CE

Host: Richard Johnson, MD Guest: Abdul Abdellatif, MD, FASN This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Host: Abdul Abdellatif, MD, FASN Guest: Richard Johnson, MD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Host: Richard Johnson, MD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and...

Host: Richard Johnson, MD Guest: Brittany Weber, MD, PhD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney dise...

Host: Richard Johnson, MD Guest: John K. Botson, MD, RPh This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney dise...

Host: Richard Johnson, MD Guest: John K. Botson, MD, RPh This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney dise...

Host: Abdul Abdellatif, MD, FASN Guest: Richard Johnson, MD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Host: Abdul Abdellatif, MD, FASN Guest: John K. Botson, MD, RPh This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidn...

Host: John K. Botson, MD, RPh Guest: Abdul Abdellatif, MD, FASN This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidn...

Host: Richard Johnson, MD Guest: Abdul Abdellatif, MD, FASN This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Host: Richard Johnson, MD Guest: Abdul Abdellatif, MD, FASN This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Host: Abdul Abdellatif, MD, FASN Guest: Richard Johnson, MD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Host: Richard Johnson, MD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and...

Host: Nirav Y. Raval, MD, FACC Guest: Gurusher Panjrath, MD, FACC, FAHA, FHFSA This program is no longer available for credit. Despite the use of guideline-directed medical therapy, many patients with heart failure continue to have worsening symptoms. Enter baroreflex activation therapy, or BAT, an implantable FDA-approved cardiac autonomic modulation device. Listen in as Drs. Nirav Raval and Guru...

Host: Nirav Y. Raval, MD, FACC Guest: Gurusher Panjrath, MD, FACC, FAHA, FHFSA This program is no longer available for credit. Despite the use of guideline-directed medical therapy, many patients with heart failure continue to have worsening symptoms. Enter baroreflex activation therapy, or BAT, an implantable FDA-approved cardiac autonomic modulation device. Listen in as Drs. Nirav Raval and Guru...

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Roberto Romero, MD, DMedSci This program is no longer available for credit. Renowned international expert Dr. Roberto Romero joins Dr. Lee Shulman to walk us through maternal anti-fetal rejection. Find out about its pathophysiology, mechanisms of disease, approach to diagnosis, and potential treatment so that you can broaden your understanding and impr...

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Roberto Romero, MD, DMedSci This program is no longer available for credit. Renowned international expert Dr. Roberto Romero joins Dr. Lee Shulman to walk us through maternal anti-fetal rejection. Find out about its pathophysiology, mechanisms of disease, approach to diagnosis, and potential treatment so that you can broaden your understanding and impr...

Host: Frederic Rahbari-Oskoui, MD, MSc This program is no longer availble for credit This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.

Host: Frederic Rahbari-Oskoui, MD, MSc This program is no longer availble for credit This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.

Host: Fouad T. Chebib, MD Guest: Pranav S. Garimella, MD This program is no longer availble for credit This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.

Host: Fouad T. Chebib, MD Guest: Pranav S. Garimella, MD This program is no longer availble for credit This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.

Host: Mark Socinski, MD Guest: Patrick Forde, M.B.B.Ch. Guest: Karen Reckamp, MS, MD Non-small cell lung cancer (NSCLC) is a highly heterogeneous disease, and research has evolved its diagnosis and treatment through the discovery of genetic alterations and molecular pathways, personalizing treatment based on tumor mutation(s). The molecular characterization of tumors using techniques such as next-...

Host: Mark Socinski, MD Guest: Patrick Forde, M.B.B.Ch. Guest: Karen Reckamp, MS, MD Non-small cell lung cancer (NSCLC) is a highly heterogeneous disease, and research has evolved its diagnosis and treatment through the discovery of genetic alterations and molecular pathways, personalizing treatment based on tumor mutation(s). The molecular characterization of tumors using techniques such as next-...

Host: Meyeon Park, MD, MAS Host: Anjay Rastogi, MD, PhD This Expert Exchange webcast is designed to help improve clinicians’ ability to utilize prognostic tools to monitor disease progression and implement appropriate treatment strategies in patients with ADPKD. This activity is not available for continuing education credit.

Host: Meyeon Park, MD, MAS Host: Anjay Rastogi, MD, PhD This Expert Exchange webcast is designed to help improve clinicians’ ability to utilize prognostic tools to monitor disease progression and implement appropriate treatment strategies in patients with ADPKD. This activity is not available for continuing education credit.